The United States Food and Drug Administration (FDA) has granted Orphan Drug Designations (ODD) to United States-based Viracta Therapeutics, Incorporated's Phase two drug candidate, nanatinostat, in combination with the antiviral valganciclovir intended for the treatment of post-transplant lymphoproliferative disorder (PTLD), plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma, it was reported yesterday.
The therapeutic approach is being investigated in a Phase 1b/2 clinical trial of Epstein Barr Virus (EBV) -associated lymphomas, including the Orphan Drug Designations granted subtypes.
The product is an oral histone deacetylase inhibitor that is being investigated in a range of clinical indications. The company says that Viracta's unique treatment approach holds potential to become the first targeted, orally administered epigenetic therapy for EBV-associated cancers.
Drugs that receive ODD from the FDA, such as nanatinostat, obtain seven years of marketing exclusivity, tax credits for clinical trial costs, marketing application filing fee waivers and assistance from the FDA in the drug development process.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT